These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31648558)

  • 1. Immune-related dermatologic toxicities: to make a long story short.
    Angelaki A; Lampropoulou DI; Aravantinos G
    Cutan Ocul Toxicol; 2020 Mar; 39(1):10-12. PubMed ID: 31648558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Sandigursky S; Mor A
    Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supportive care for patients undergoing immunotherapy.
    Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
    Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations.
    Gremese E; Alivernini S; Ferraccioli ES; Ferraccioli G
    Clin Immunol; 2020 May; 214():108395. PubMed ID: 32240819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-related adverse events of immune checkpoint inhibitors: a brief review.
    Myers G
    Curr Oncol; 2018 Oct; 25(5):342-347. PubMed ID: 30464684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of immune-related adverse events resulting from immune checkpoint blockade.
    Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C; Martin Romano P; Voisin AL; Danlos FX; Champiat S; Laghouati S; Kfoury M; Vincent H; Postel-Vinay S; Varga A; Vuagnat P; Ribrag V; Mezquita L; Besse B; Hollebecque A; Lambotte O; Michot JM; Soria JC; Massard C; Marabelle A
    Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
    Khan OF; Monzon J
    Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy.
    Calabrese L; Mariette X
    Ann Rheum Dis; 2018 Feb; 77(2):162-164. PubMed ID: 28928270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dermatologic toxicities of immune checkpoint inhibitors].
    Sibaud V; Boulinguez S; Pagès C; Riffaud L; Lamant L; Chira C; Boyrie S; Vigarios E; Tournier E; Meyer N
    Ann Dermatol Venereol; 2018 May; 145(5):313-330. PubMed ID: 29678394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.